Venus Remedies has announced that the company has received approval from the Drug Controller General of India to launch Cephalosporin, used in the treatment of Cystic Fibrosis.

Cystic fibrosis is a hereditary disease that mainly affects the lungs and digestive system, causing progressive disability and early death for some patients.

The Company is all set to launch this innovative therapy for APE/Cystis Fibrosis patients after completion of the multi-centered Phase II Clinical Trials. The commercial launch of this product shall be a boon to the Cystis Fibrosis patients being the only solution for the treatment of life threatening infections caused by P Aeruginosa / MRSA in these patients.

This new FDC shall be launched under Strategic Marketing tie-up with leading Indian Pharma Companies in the Rs 2 billion domestic market and is expected to be a segment leader within 2 years of its launch.

The company has already filed patent applications for the product in 50 countries and will launch the product all over the world very shortly.